Selected research
Market Analysis & Forecast
Global AI Pharmaceutical Market Analysis and Forecast 2026-2032
Market perspective
The global AI Pharmaceutical market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for AI Pharmaceutical is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for AI Pharmaceutical is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for AI Pharmaceutical is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for AI Pharmaceutical is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of AI Pharmaceutical include Noetik, Atomwise, Cradle, Exscientia, Iktos, Insilico Medicine, BenevolentAI, Cyclica and Recursion, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for AI Pharmaceutical, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of AI Pharmaceutical, also provides the revenue of main regions and countries. Of the upcoming market potential for AI Pharmaceutical, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the AI Pharmaceutical revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global AI Pharmaceutical market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for AI Pharmaceutical revenue, projected growth trends, production technology, application and end-user industry.
AI Pharmaceutical Segment by Company
Noetik
Atomwise
Cradle
Exscientia
Iktos
Insilico Medicine
BenevolentAI
Cyclica
Recursion
Auransa
InveniAI
Pfizer
IBM
AI Pharmaceutical Segment by Type
Artificial intelligence (AI)
Machine Learning (ML)
Others
AI Pharmaceutical Segment by Application
Drug Discovery
Clinical Trials
Others
AI Pharmaceutical Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Pharmaceutical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Pharmaceutical and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Pharmaceutical.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of AI Pharmaceutical in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of AI Pharmaceutical company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, AI Pharmaceutical revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Artificial intelligence (AI)
- Machine Learning (ML)
- Others
Applications
- Drug Discovery
- Clinical Trials
- Others
Companies covered
- Noetik
- Atomwise
- Cradle
- Exscientia
- Iktos
- Insilico Medicine
- BenevolentAI
- Cyclica
- Recursion
- Auransa
- InveniAI
- Pfizer
- IBM
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 AI Pharmaceutical Market by Type
- 1.2.1 Global AI Pharmaceutical Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Artificial intelligence (AI)
- 1.2.3 Machine Learning (ML)
- 1.2.4 Others
- 1.3 AI Pharmaceutical Market by Application
- 1.3.1 Global AI Pharmaceutical Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Drug Discovery
- 1.3.3 Clinical Trials
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 AI Pharmaceutical Market Dynamics
- 2.1 AI Pharmaceutical Industry Trends
- 2.2 AI Pharmaceutical Industry Drivers
- 2.3 AI Pharmaceutical Industry Opportunities and Challenges
- 2.4 AI Pharmaceutical Industry Restraints
3 Global Growth Perspective
- 3.1 Global AI Pharmaceutical Market Perspective (2021-2032)
- 3.2 Global AI Pharmaceutical Growth Trends by Region
- 3.2.1 Global AI Pharmaceutical Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global AI Pharmaceutical Market Size by Region (2021-2026)
- 3.2.3 Global AI Pharmaceutical Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global AI Pharmaceutical Revenue by Players
- 4.1.1 Global AI Pharmaceutical Revenue by Players (2021-2026)
- 4.1.2 Global AI Pharmaceutical Revenue Market Share by Players (2021-2026)
- 4.1.3 Global AI Pharmaceutical Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global AI Pharmaceutical Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global AI Pharmaceutical Key Players Headquarters & Area Served
- 4.4 Global AI Pharmaceutical Players, Product Type & Application
- 4.5 Global AI Pharmaceutical Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global AI Pharmaceutical Market CR5 and HHI
- 4.6.3 2025 AI Pharmaceutical Tier 1, Tier 2, and Tier 3
5 AI Pharmaceutical Market Size by Type
- 5.1 Global AI Pharmaceutical Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global AI Pharmaceutical Revenue by Type (2021-2032)
- 5.3 Global AI Pharmaceutical Revenue Market Share by Type (2021-2032)
6 AI Pharmaceutical Market Size by Application
- 6.1 Global AI Pharmaceutical Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global AI Pharmaceutical Revenue by Application (2021-2032)
- 6.3 Global AI Pharmaceutical Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Noetik
- 7.1.1 Noetik Company Information
- 7.1.2 Noetik Business Overview
- 7.1.3 Noetik AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.1.4 Noetik AI Pharmaceutical Product Portfolio
- 7.1.5 Noetik Recent Developments
- 7.2 Atomwise
- 7.2.1 Atomwise Company Information
- 7.2.2 Atomwise Business Overview
- 7.2.3 Atomwise AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.2.4 Atomwise AI Pharmaceutical Product Portfolio
- 7.2.5 Atomwise Recent Developments
- 7.3 Cradle
- 7.3.1 Cradle Company Information
- 7.3.2 Cradle Business Overview
- 7.3.3 Cradle AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.3.4 Cradle AI Pharmaceutical Product Portfolio
- 7.3.5 Cradle Recent Developments
- 7.4 Exscientia
- 7.4.1 Exscientia Company Information
- 7.4.2 Exscientia Business Overview
- 7.4.3 Exscientia AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.4.4 Exscientia AI Pharmaceutical Product Portfolio
- 7.4.5 Exscientia Recent Developments
- 7.5 Iktos
- 7.5.1 Iktos Company Information
- 7.5.2 Iktos Business Overview
- 7.5.3 Iktos AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.5.4 Iktos AI Pharmaceutical Product Portfolio
- 7.5.5 Iktos Recent Developments
- 7.6 Insilico Medicine
- 7.6.1 Insilico Medicine Company Information
- 7.6.2 Insilico Medicine Business Overview
- 7.6.3 Insilico Medicine AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.6.4 Insilico Medicine AI Pharmaceutical Product Portfolio
- 7.6.5 Insilico Medicine Recent Developments
- 7.7 BenevolentAI
- 7.7.1 BenevolentAI Company Information
- 7.7.2 BenevolentAI Business Overview
- 7.7.3 BenevolentAI AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.7.4 BenevolentAI AI Pharmaceutical Product Portfolio
- 7.7.5 BenevolentAI Recent Developments
- 7.8 Cyclica
- 7.8.1 Cyclica Company Information
- 7.8.2 Cyclica Business Overview
- 7.8.3 Cyclica AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.8.4 Cyclica AI Pharmaceutical Product Portfolio
- 7.8.5 Cyclica Recent Developments
- 7.9 Recursion
- 7.9.1 Recursion Company Information
- 7.9.2 Recursion Business Overview
- 7.9.3 Recursion AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.9.4 Recursion AI Pharmaceutical Product Portfolio
- 7.9.5 Recursion Recent Developments
- 7.10 Auransa
- 7.10.1 Auransa Company Information
- 7.10.2 Auransa Business Overview
- 7.10.3 Auransa AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.10.4 Auransa AI Pharmaceutical Product Portfolio
- 7.10.5 Auransa Recent Developments
- 7.11 InveniAI
- 7.11.1 InveniAI Company Information
- 7.11.2 InveniAI Business Overview
- 7.11.3 InveniAI AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.11.4 InveniAI AI Pharmaceutical Product Portfolio
- 7.11.5 InveniAI Recent Developments
- 7.12 Pfizer
- 7.12.1 Pfizer Company Information
- 7.12.2 Pfizer Business Overview
- 7.12.3 Pfizer AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.12.4 Pfizer AI Pharmaceutical Product Portfolio
- 7.12.5 Pfizer Recent Developments
- 7.13 IBM
- 7.13.1 IBM Company Information
- 7.13.2 IBM Business Overview
- 7.13.3 IBM AI Pharmaceutical Revenue and Gross Margin (2021-2026)
- 7.13.4 IBM AI Pharmaceutical Product Portfolio
- 7.13.5 IBM Recent Developments
8 North America
- 8.1 North America AI Pharmaceutical Revenue (2021-2032)
- 8.2 North America AI Pharmaceutical Revenue by Type (2021-2032)
- 8.2.1 North America AI Pharmaceutical Revenue by Type (2021-2026)
- 8.2.2 North America AI Pharmaceutical Revenue by Type (2027-2032)
- 8.3 North America AI Pharmaceutical Revenue Share by Type (2021-2032)
- 8.4 North America AI Pharmaceutical Revenue by Application (2021-2032)
- 8.4.1 North America AI Pharmaceutical Revenue by Application (2021-2026)
- 8.4.2 North America AI Pharmaceutical Revenue by Application (2027-2032)
- 8.5 North America AI Pharmaceutical Revenue Share by Application (2021-2032)
- 8.6 North America AI Pharmaceutical Revenue by Country
- 8.6.1 North America AI Pharmaceutical Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America AI Pharmaceutical Revenue by Country (2021-2026)
- 8.6.3 North America AI Pharmaceutical Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe AI Pharmaceutical Revenue (2021-2032)
- 9.2 Europe AI Pharmaceutical Revenue by Type (2021-2032)
- 9.2.1 Europe AI Pharmaceutical Revenue by Type (2021-2026)
- 9.2.2 Europe AI Pharmaceutical Revenue by Type (2027-2032)
- 9.3 Europe AI Pharmaceutical Revenue Share by Type (2021-2032)
- 9.4 Europe AI Pharmaceutical Revenue by Application (2021-2032)
- 9.4.1 Europe AI Pharmaceutical Revenue by Application (2021-2026)
- 9.4.2 Europe AI Pharmaceutical Revenue by Application (2027-2032)
- 9.5 Europe AI Pharmaceutical Revenue Share by Application (2021-2032)
- 9.6 Europe AI Pharmaceutical Revenue by Country
- 9.6.1 Europe AI Pharmaceutical Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe AI Pharmaceutical Revenue by Country (2021-2026)
- 9.6.3 Europe AI Pharmaceutical Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China AI Pharmaceutical Revenue (2021-2032)
- 10.2 China AI Pharmaceutical Revenue by Type (2021-2032)
- 10.2.1 China AI Pharmaceutical Revenue by Type (2021-2026)
- 10.2.2 China AI Pharmaceutical Revenue by Type (2027-2032)
- 10.3 China AI Pharmaceutical Revenue Share by Type (2021-2032)
- 10.4 China AI Pharmaceutical Revenue by Application (2021-2032)
- 10.4.1 China AI Pharmaceutical Revenue by Application (2021-2026)
- 10.4.2 China AI Pharmaceutical Revenue by Application (2027-2032)
- 10.5 China AI Pharmaceutical Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia AI Pharmaceutical Revenue (2021-2032)
- 11.2 Asia AI Pharmaceutical Revenue by Type (2021-2032)
- 11.2.1 Asia AI Pharmaceutical Revenue by Type (2021-2026)
- 11.2.2 Asia AI Pharmaceutical Revenue by Type (2027-2032)
- 11.3 Asia AI Pharmaceutical Revenue Share by Type (2021-2032)
- 11.4 Asia AI Pharmaceutical Revenue by Application (2021-2032)
- 11.4.1 Asia AI Pharmaceutical Revenue by Application (2021-2026)
- 11.4.2 Asia AI Pharmaceutical Revenue by Application (2027-2032)
- 11.5 Asia AI Pharmaceutical Revenue Share by Application (2021-2032)
- 11.6 Asia AI Pharmaceutical Revenue by Country
- 11.6.1 Asia AI Pharmaceutical Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia AI Pharmaceutical Revenue by Country (2021-2026)
- 11.6.3 Asia AI Pharmaceutical Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA AI Pharmaceutical Revenue (2021-2032)
- 12.2 SAMEA AI Pharmaceutical Revenue by Type (2021-2032)
- 12.2.1 SAMEA AI Pharmaceutical Revenue by Type (2021-2026)
- 12.2.2 SAMEA AI Pharmaceutical Revenue by Type (2027-2032)
- 12.3 SAMEA AI Pharmaceutical Revenue Share by Type (2021-2032)
- 12.4 SAMEA AI Pharmaceutical Revenue by Application (2021-2032)
- 12.4.1 SAMEA AI Pharmaceutical Revenue by Application (2021-2026)
- 12.4.2 SAMEA AI Pharmaceutical Revenue by Application (2027-2032)
- 12.5 SAMEA AI Pharmaceutical Revenue Share by Application (2021-2032)
- 12.6 SAMEA AI Pharmaceutical Revenue by Country
- 12.6.1 SAMEA AI Pharmaceutical Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA AI Pharmaceutical Revenue by Country (2021-2026)
- 12.6.3 SAMEA AI Pharmaceutical Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst